Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Tallarek, AC; Huppertz, B; Stepan, H.
Preeclampsia - Aetiology, Current Diagnostics and Clinical Management, New Therapy Options and Future Perspectives
GEBURTSH FRAUENHEILK. 2012; 72(12): 1107-1116.
Doi: 10.1055/s-0032-1328080
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Huppertz Berthold
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Preeclampsia is a multisystem disease for which the exact causes have not yet been sufficiently clarified. However, in the past few years it has become clear that a placental imbalance between angiogenic and anti-angiogenic proteins is the decisive pathogenetic factor for the occurrence of preeclampsia. With the possibility to measure these angiogenic factors (sFlt-1/PlGF ratio) in maternal blood full new diagnostic possibilities have been opened that enable the certain diagnosis or exclusion of the diseases as well as a short-term prognosis to be made. In secondary prevention the current data situation for ASA confirms a moderate but measurable utility. The management concept depends on gestational age. In the case of early clinical manifestations (< 34th week of pregnancy) the clinical management in a perinatal centre remains unchanged with foeto-maternal monitoring and induction of pulmonary maturation, symptomatic therapy under careful blood pressure lowering and determination of the optimal delivery time. A balance must be made here between foetal immaturity and maternal risks upon prolongations. The pathomechanism of anti-angiogenic overload with sFlt-1 provides a starting point for first therapeutic interventions. The present article gives an overview of current diagnostic options and presents possible future therapeutic perspectives for discussion.
- Find related publications in this database (Keywords)
-
hypertensive diseases of pregnancy
-
preeclampsia
-
angiogenic balance